Parabilis Prices Record-Breaking $670M Biotech IPO
Strategic News Watch — June 10, 2026
Dealmaking and fresh regulatory progress led today’s biopharma developments, headlined by AlzeCure’s $1 billion Eli Lilly licensing deal and Parabilis’ record-breaking $670M biotech IPO.
Today’s top developments:
- AlzeCure secured a $1 billion licensing deal with Eli Lilly (Pharmaceutical Executive)
- Parabilis priced a record-breaking $670M biotech IPO (BioPharma Dive)
- Lilly’s Ebglyss won FDA approval for less-frequent dosing in eczema (pharmaphorum)
- Bayer’s asundexian entered EMA review for secondary stroke prevention (pharmaphorum)
What to Watch
- Next-Gen Obesity Data: Additional CagriSema efficacy readouts from Novo Nordisk will be critical in positioning the asset against Lilly’s retatrutide as both companies vie for market share beyond first-generation GLP-1s.
- Factor XIa Race: Bayer’s asundexian EMA review puts pressure on BMS/J&J to accelerate their FXIa program, with the winner potentially capturing a multibillion-dollar anticoagulation franchise defined by superior safety profiles.
- Biotech IPO Window: Parabilis’ record $670M raise suggests public markets remain receptive to well-differentiated science stories, creating opportunity for other late-preclinical and early-clinical biotechs to access growth capital.
- Dosing Differentiation in Dermatology: Ebglyss’ less-frequent dosing approval may shift prescribing dynamics in atopic dermatitis, where patient preference and real-world adherence increasingly influence payer and physician choices over pure efficacy data.
This brief highlights today’s top stories. Read the latest edition → for all stories, source links, and analysis.
